Daniel Mertens

12PUBLICATIONS
28CO-AUTHORS
Molecular targetsMedical molecular engineering of nucleic acids and proteinsCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursHardware security
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jul 10, 2025
A noncoding mutation in the NOTCH1 gene initiates oncogenic NOTCH signaling via wild-type NICD stabilization in CLL.

Min Guo, Tugba Memis, Alena Sophie Ehrmann

|Jun 02, 2025
NOTCH1 signaling is dysregulated by loss of the deubiquitinase USP28 with del(11q), uncovering USP28 inhibition as novel therapeutic target in CLL.

Alena Sophie Ehrmann, Miguel Quijada-Álamo, Viola Close

|Jan 20, 2023
Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors.

Jialei Qi, Sascha Endres, Deyan Yordanov Yosifov

|Jan 08, 2023
To β or Not to β: How Important Is β-Catenin Dependent and Independent WNT Signaling in CLL?

Karol D Urbanek, Stephan Stilgenbauer, Daniel Mertens

|May 09, 2022
Modeling the B-cell receptor signaling on single cell level reveals a stable network circuit topology between nonmalignant B cells and chronic lymphocytic leukemia cells and between untreated cells and cells treated with kinase inhibitors.

Christine Wolf, Carsten Maus, Michael R O Persicke

|Oct 18, 2021
Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia.

Billy Michael Chelliah Jebaraj, Annika Müller, Rashmi Priyadharshini Dheenadayalan

Pageof 2

Frequent Collaborators

5 joint publications

Deyan Yordanov Yosifov

2 joint publications

Christine Wolf

2 joint publications

Tilman Borggrefe

2 joint publications

Peter Gierschik